GSK264220A
Based on 1 publication(s) in Google Scholar
GSK264220A is a potent endothelial lipase inhibitor with IC50 of 16 nM. GSK264220A has the potential to decrease the risk of cardiovascular disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.31%
- CAS No.: 685506-42-7
- Formule: C17H21N3O4S
- Masse moléculaire:363.43
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-117549
IbrolipimLPL Activator -
HY-128144
Lalistat 2LAL Inhibitor -
HY-10528
TasquinimodS100A9 Inhibitor -
HY-P1119
WRW4FPRL1 Antagonist -
HY-103372R
GSK264220A (Standard)Reference Standard -
HY-14471
CetilistatLipase Inhibitor -
HY-14471R
Cetilistat (Standard)Lipase Inhibitor -
HY-B1488
Tacrine hydrochlorideCholinesterase Inhibitor -
HY-B0841
AcephateInsecticide -
HY-N2320
Physostigmine hemisulfateCholinesterase (ChE) Inhibitor -
HY-B0732
Itopride hydrochlorideAChE/D2DR Inhibitor -
HY-106901A
Asoxime dichlorideAChE Reversible Inhibitor
Publications Citing Use of MedChemExpress (MCE) GSK264220A
More
Activité biologique
Description
Chemical Information
-
CAS No. 685506-42-7
-
Appearance Solid
-
Masse moléculaire 363.43
-
Formule C17H21N3O4S
-
Color White to off-white
-
SMILES
O=C(NC1=C(C)OC(S(=O)(N2CCCCC2)=O)=C1)NC3=CC=CC=C3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Pharmaceuticals (Basel)
IL-33-Driven Macrophage Reprogramming as a Potential Immunometabolic Strategy for Herpes Simplex Keratitis. [Abstract]2026 Feb 8;19(2):285. PMID: 41754825
Solvant et solubilité
In Vitro:
DMSO : ≥ 100 mg/mL (275.16 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.88 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.88 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7516 mL | 13.7578 mL | 27.5156 mL | 68.7890 mL |
| 5 mM | 0.5503 mL | 2.7516 mL | 5.5031 mL | 13.7578 mL | |
| 10 mM | 0.2752 mL | 1.3758 mL | 2.7516 mL | 6.8789 mL | |
| 15 mM | 0.1834 mL | 0.9172 mL | 1.8344 mL | 4.5859 mL | |
| 20 mM | 0.1376 mL | 0.6879 mL | 1.3758 mL | 3.4395 mL | |
| 25 mM | 0.1101 mL | 0.5503 mL | 1.1006 mL | 2.7516 mL | |
| 30 mM | 0.0917 mL | 0.4586 mL | 0.9172 mL | 2.2930 mL | |
| 40 mM | 0.0688 mL | 0.3439 mL | 0.6879 mL | 1.7197 mL | |
| 50 mM | 0.0550 mL | 0.2752 mL | 0.5503 mL | 1.3758 mL | |
| 60 mM | 0.0459 mL | 0.2293 mL | 0.4586 mL | 1.1465 mL | |
| 80 mM | 0.0344 mL | 0.1720 mL | 0.3439 mL | 0.8599 mL | |
| 100 mM | 0.0275 mL | 0.1376 mL | 0.2752 mL | 0.6879 mL |
GSK264220A Related Classifications
HY-103372 Related Classifications
Powered by Bioz